Efficacy of pembrolizumab in combination with concurrent chemoradiotherapy - Medizinonline

According to the final analysis of KEYNOTE-799 [1], pembrolizumab in combination with concurrent chemoradiotherapy (cCRT) showed sustained efficacy in patients with unresectable, locally advanced stage III NSCLC after five years of follow-up. Further evaluation of the treatment regimen is underway.

Dieser Inhalt ist nur für Benutzer der Gruppe: Medizinische Fachperson zugänglich
Jetzt beitreten

Already a member? Log in here

Autoren

Birke Dikken

Publikation

InFo ONKOLOGIE & HÄMATOLOGIE
InFo PNEUMOLOGIE & ALLERGOLOGIE

Related Topics

Previous Article

Dementia

Recognize incipient progression and identify countermeasures

Immune sensors

Dysfunctional signaling pathways in cardiomyocytes and their role in heart disease

You May Also Like

12 min

Cardiology and Nutrition

Ultra-Processed Foods and Cardiovascular Risk—The New AHA Position Statement

12 min

The Brain and the Motivation to Eat

Why is it so hard to lose weight?

9 min

Breast (HR+) and Endometrial Cancer

A Comparison of Hormone-Dependent Female Tumors

- RX
- Education
- Gynecology
- Oncology
- Studies

8 min

Chronic Urticaria: Treatment for Patients Unresponsive to Antihistamines

In addition to anti-IgE antibodies, the guideline recommends anti-IL-4α antibodies and BTK inhibition

6 min

Type 1 Diabetes in Childhood

Early Impairment of Glucagon Counterregulation

7 min

Psychosis in Parkinson's Disease

Be Careful When Choosing Medications

3 min

Esophageal Cancer

A Comparison of Endoscopic and Surgical Innovations

- RX
- Education
- Oncology
- ORL
- Studies

6 min

PMR and LVV: Current EULAR Recommendations

Polymyalgia rheumatica, giant cell arteritis, and Takayasu arteritis

Input your search keywords and press Enter.